Double-blind trial of miconazole in dermatomycosis
A double-blind study of miconazole (Brentan®) has been performed in 86 patients suffering from dermatomycosis. Of the 65 patients not lost to follow-up, 30 had received the active drug, and 35 placebo. The cure-rate was significantly (p=0.03) higher in patients receiving miconazole (70%) than in those on placebo (40%). The higher cure-rate was found in patients suffering from cutaneous candidiasis and tinea versicolor, as well as from dermatophytosis, but was significant only in the latter group, which was the largest.